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ABSTRACT
DNA mismatch repair in Escherichia coli has been
shown to be involved in two distinct processes: muta-
tion avoidance, which removes potential mutations
arising as replication errors, and antirecombination
which prevents recombination between related, but
not identical (homeologous), DNA sequences. We
show that cells with the mutSD800 mutation (which
removes the C-terminal 53 amino acids of MutS)
on a multicopy plasmid are proficient for mutation
avoidance. In interspecies genetic crosses, however,
recipients with the mutSD800 mutation show
increased recombination by up to 280-fold relative
to mutS1. The MutSD800 protein binds to O6-methyl-
guanine mismatches but not to intrastrand platinated
GG cross-links, explaining why dam bacteria with
the mutSD800 mutation are resistant to cisplatin,
but not MNNG, toxicity. The results indicate that the
C-terminal end of MutS is necessary for antirecom-
bination and cisplatin sensitization, but less signific-
ant for mutation avoidance. The inability of MutSD800
to form tetramers may indicate that these are the
active form of MutS.
INTRODUCTION
The Dam-directed mismatch repair (MMR) system of
Escherichia coli removes potential mutations arising as
replication errors (mutation avoidance) (1–3). Correction of
biosynthetic errors by MMR occurs directly after replication,
just behind the replication fork, where the parental DNA
strand is fully methylated at GATC (dam) sequences and the
newly synthesized strand is not yet methylated. When base
mispairs arise in such hemi-methylated DNA, they are bound
initially by the MutS protein which subsequently recruits MutL
and MutH to form a ternary complex. Incision by activated
MutH occurs on the unmethylated strand at a nearby GATC
sequence, followed by excision, in either the 30 or 50 direction,
of the mismatched base pair and surrounding sequence.
Re-synthesis by the replicative polymerase, DNA polymerase
III, restores the correct nucleotide sequence and the resulting
nick is sealed by DNA ligase to complete the repair process.
Subsequently, the repaired DNA strand is methylated at
GATC sequences by Dam methyltransferase and this methyla-
tion prevents further MMR action. This model has both gen-
etic and biochemical support including a mutator phenotype
associated with mutS mutants (1,2).
MMR also plays a role in preventing recombination
between related, but not identical (homeologous), DNA
sequences (anti-recombination) (4). Genetic crosses between
E.coli and Salmonella enterica Serovar Typhimurium are
sterile unless the recipient contains mutations in the mutS
or mutL MMR genes. This result suggests that MMR either
impedes or actively reverses recombination intermediates or
destroys them, with the former having some experimental
support (5–7). On a biochemical level, MutS and MutL
block RecA-mediated strand exchange between the fd and
M13 genomes, which are 3% divergent, but not between
M13–M13 genomes (8). In the homeologous reaction, MutS
has a greater effect than MutL, which is effective only in
combination with MutS. The intimate connection between
mutation avoidance and antirecombination is shown by the
phenotype of E.coli mutS mutations which are defective
in both these processes (4). A survey of a large number of
E.coli mutS mutants failed to detect any with only one of the
phenotypes (9). Similarly, we have been unable to find a
mutant with only one of these phenotypes among a collection
of dominant-negative alleles (10).
E.coli dam mutants are more sensitive to the cytotoxic
action of cisplatin and N-methyl-N0-nitro-N-nitrosoguanidine
(MNNG) than wild type (11,12). Mutations in genes that
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incapacitate MMR (mutS, mutL or mutH) in a dam background
confer a level of resistance to these agents similar to that of the
wild type. This result indicates that inappropriate MMR on
chemically modified DNA can sensitize dam cells to these
cytotoxic agents (11–13). MMR in wild-type cells is restricted
to one strand in the hemimethylated region behind the rep-
lication fork because MutH endonuclease cannot use fully
methylated DNA as a substrate. In dam mutants, however,
MMR can occur on either strand anywhere on the chromosome
because MutH can use unmethylated DNA as a substrate. It
has been proposed that MMR-induced single-strand breaks or
gaps can be converted to double-strand breaks (DSBs) either
by MutH action at the same GATC sequence on the opposite
strand (14) or by replication fork collapse (15,16). The DSBs
so formed require recombination for their repair thereby
making recombination essential for viability (15). As a result
of these DSBs, recombination capacity is limiting (15) and
when dam cells are exposed to cisplatin a large number of
DSBs accumulate (16). MMR is required for the formation of
cisplatin-induced DSBs (16) suggesting that they probably
occur at cisplatin lesions undergoing MMR at either unrep-
licated lesions or those formed with mismatches after the
action of translesion polymerases. The accumulation of DSBs
in dam mutants, which have limited recombination capacity,
and the reduced ability of MutS to prevent RecA-mediated
strand transfer of platinated DNA during recombinational
repair (17) provides a plausible model to explain why MMR
sensitizes dam cells to cisplatin.
To explain MMR sensitization of E.coli dam mutants by
MNNG, the ‘futile cycling’ model was proposed (11). In this
model, the replicative polymerase inserts either a T or C
opposite template O6-methylguanine (O6-meG). Since neither
of these bases is considered a ‘good’ match by the MMR
system, a futile cycle of insertion and removal ensues prevent-
ing progression of the replication fork. Such futile cycling in
dam mutants can also occur at sites away from the replication
fork as a consequence of MMR recognition and MutH incision
on unmethylated DNA at O6-meG–C base pairs to promote
DSB formation (13).
The MutS protein binds specifically to heteroduplex DNA
containing base mismatches (18) or with greatest affinity to
small insertion/deletion loops (IDLs) (19). It also binds plat-
inated GG intrastrand cross-links (20) and O6-meG mispaired
with either C or T (21). The crystal structure of E.coli MutS
bound to an oligonucleotide with a G–T mismatch has been
solved using a derivative of the MutS protein, MutSD800,
which lacks the C-terminal 53 amino acids (22). The
MutSD800 mutant crystallizes as a dimer and retains the abil-
ity to bind DNA and ATP, just as full-length MutS does (22).
Further analysis into the properties of the MutS and MutSD800
proteins by equilibrium sedimentation and gel filtration show
that MutS dimers can assemble into higher order oligomeric
structures, while the MutSD800 mutant is restricted to dimer
formation only (23). The ability of MutS to form tetramers
suggests this oligomeric state is important in MutS function.
A similar conclusion was reached with the MutS protein from
Thermus species (24,25) for which a crystal structure is also
available (26).
In this report, we show that the C-terminal end of MutS is
critical for antirecombination and cisplatin sensitization, but
less significant for mutation avoidance.
MATERIALS AND METHODS
Strains, plasmids and media
Strains GM3819 (Ddam-16::Kan), GM4799 (mutS458::
mTn10Kan), GM5550 (recA56 mutS458::mTn10Kan) and
GM5556 (Ddam-16::Kan mutS215::Tn10) are derivatives
of AB1157 (thr-1 ara-14 leuB6 D(gpt-proA)62 lacY1 tsx-33
supE44 galK2 hisG4 rfbD1 mgl-51 rpsL31 kdgK51 xyl-5 mtl-1
argE3 thi-1). AB259 (HfrH) was obtained from E.A. Adelberg
(Yale University). Salmonella strains SA536 and SA977 were
obtained from the Salmonella Genetic Stock Centre, Univer-
sity of Calgary, Canada. Plasmids with the mutSDC800 (22)
(referred to as mutSD800 in this paper) and mutSD680 (27)
were derived from pMQ372 (27) carrying the mutS+ gene. Full
descriptions of strains and plasmids can be found at http://
users.umassmed.edu/martin.marinus/dstrains.html. Bacterio-
logical media have been described previously (15,28) except
for the MacConkey Agar Base (Difco) medium which was
supplemented with 50 g/l galactose. Ampicillin, rifampicin
and streptomycin were included in media, when required,
at 100 mg/ml.
Estimation of mutant frequency, conjugational crosses
and cytotoxicity
Spontaneous mutant frequencies were measured as described
elsewhere (28,29) and conjugation experiments were per-
formed as described previously (15) except that mating
mixtures were incubated for 1 h at 37C for homologous
crosses and 3 h for the homeologous crosses. Cell survival
after exposure to cisplatin or MNNG was measured as
described previously (11,29).
Proteins and DNA
MutS protein was purchased from USB and dialyzed before use
against 20 mM KPO4, pH 7.4, 0.1 mM EDTA, 1 mM PMSF
and 10 mM beta-mercaptoethanol. We found that heteroduplex
binding (see below) and ATPase specific activity (data not
shown) were the same as that for the MutSD800 protein.
MutL protein was a gift from F. Lopez de Saro and
M. O’Donnell (Rockefeller University). MutSD800 was puri-
fied from strain GM7854 [pmutSD800/BL21(lambdaDE3)].
Briefly, the cells were grown at 37C to an OD600 of 0.8 and
shifted to 26C for induction with 1 mM IPTG. The cells were
grown for an additional 3 h at 26C before harvesting. The cells
were lysed using a Microfluidizer (Microfluidics Corp.) and
then centrifuged at 27 000 g for 30 min. The supernatant was
treated with streptomycin sulfate and ammonium sulfate as
described previously (18). The resulting fraction was loaded
onto a heparin agarose column (Amersham Pharmacia) and
eluted with a linear gradient of 100–400 mM KCl. The fractions
containing MutS were subsequently loaded onto a ceramic
hydroxylapatite column (Sigma) and eluted using a linear con-
centration gradient of 20–120 mM KCl. This produced a single
MutS peak eluting at 50–70 mM KCl. Fractions containing
MutSD800 were pooled, concentrated using a Centriprep col-
umn (Millipore) and frozen at 75C. The protein was at least
95% pure as determined by SDS–PAGE analysis. Protein
concentration was determined by ninhydrin analysis (30).
M13mp18 DNA RFI and single-stranded circular DNA
forms were from New England Biolabs (NEB). The RFI form
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was digested with DraIII and BglII restriction endonucleases
(NEB) to remove lac operon DNA. Single-stranded circular
DNA of bacteriophage fd was prepared by growing a culture of
strain AB259 to about 1 · 108 cells, adding fd at an m.o.i of
1 and allowing the culture to grow for an additional 3–4 h. The
culture was centrifuged to remove bacteria, and 20% poly-
ethyleneglycol 8000 and 2.5 M NaCl solution were added to
the supernatant (1:3) and left on ice for 30 min. The mixture
was centrifuged at 9500 g for 10 min and the phage pellet
resuspended in TE buffer. The DNA was phenol extracted,
ethanol precipitated and its concentration determined by UV
spectroscopy.
Heteroduplex construction, electrophoretic mobility
shift assay and RecA strand exchange assay
Heteroduplex DNA with a single IDL and labeled with P32 was
constructed and analyzed by electrophoretic mobility shift
assay as described previously (19,27). The oligonucleotide
50-ATACGGAAGTTAAAGTO6meGCGGATCATCTCTAG-30
(Sigma-Genosys) was annealed with its complementary
sequence to form either O6meG–C or O6meG–T base pairs.
A DNA oligonucleotide provided by Jennifer Robbins and
J.M. Essigmann (MIT), designated Xlink (50-CCT CTC CTT
GGT CTT CTC CTC TCC-30) contains a cisplatin cross-link
between the two guanines and was annealed to its comple-
mentary sequence to form either GG–CC or GG–CT mis-
matches. The platinated and methylated oligonucleotides
were not radiolabeled. The P32-labeled DNA and the methyl-
ated and platinated DNA, which were stained with Vistra
Green (Amersham-Pharmacia) for 1 h, were quantitated using
a Fuji Phosphorimager. RecA-mediated strand transfer was
performed and measured as described except that M13 and
fd molecules were used in place of the phiX174 molecules
used previously (17).
RESULTS
Spontaneous mutation frequency of wild-type
and mutS strains
Strain GM4799, a mutS null mutant (27), was transformed
with plasmids bearing the mutS+, mutSD680 and mutSD800
genes. The mutSD680 and mutSD800 designations indicate
where the 853 amino acid MutS protein was truncated. The
mutSD680 mutation has a null mutator phenotype and the
MutSD680 protein is unable to form oligomers and has
reduced ability to interact with MutL (27). It is used in experi-
ments presented here as the null mutS control. The transformed
strains were tested for reversion of the argE3 and galK2 mark-
ers of the host strain as well as resistance to rifampicin. The
results in Table 1 and Figure 1 show that the GM4799 strain
with the mutSD800 or mutS+ plasmids did not display a muta-
tor phenotype, but that GM4799 with mutSD680 plasmid did.
The result with rifampicin resistance for the mutSD800 and
mutS+ strains confirmed that obtained previously by Lamers
et al. (22) and Biswas et al. (31). The reversion to Arg+ and
Gal+ papillae formation was marginally higher in the GM4799
with the mutSD800 plasmid culture compared to mutS+, but
both these values were much lower than in the mutSD680
plasmid control strain. We conclude that the mutSD800 allele
does not confer a mutator phenotype to the cell.
Interspecies crosses
Strain GM4799 with each of the mutS plasmids was used as a
recipient in conjugal crosses with E.coli (homologous) or
S.enterica Serovar Typhimurium (homeologous) donors. With
the E.coli donor, AB259, recombinants were formed after
60 min of mating, at the same frequency with each GM4799
strain indicating no effect of the mutS alleles on homologous
recombination (Table 2). With the Salmonella donors SA536
or SA977, however, the GM4799 recipient with the mutSD800
plasmid formed recombinants 283- and 100-fold higher than
the wild-type recipient, respectively. These values, however,
are about half that for the GM4799 strain with the mutSD680
plasmid indicating that the mutSD800 allele does not com-
pletely relieve the inhibition produced by a fully proficient
MMR system. The level of homeologous recombination was
Table 1. Spontaneous mutant frequencies
Plasmid allele Arg+ RifR
MutS+ 4 1
mutSD680 66 72
mutSD800 8 1
Cultures of strain GM4799 (mutS null mutation) with the indicated plasmid
allele were plated on media selective for rifampicin-resistance or arginine
prototrophy. The numbers represent mutant colonies per 108 cells plated.
Table 2. Yield of recombinants in homologous and homeologous crosses
Donor Plasmid in
recipient
Recipient Selected
marker(s)
Frequency Fold
increase
AB259 mutS+ Rec+ Thr+ Leu+ 2.8 · 105 —
AB259 mutSD680 Rec+ Thr+ Leu+ 2.5 · 105 1
AB259 mutSD800 Rec+ Thr+ Leu+ 2.0 · 105 1
SA536 mutS+ Rec+ Arg+ 120 1
SA536 mutSD680 Rec+ Arg+ 59 000 492
SA536 mutSD800 Rec+ Arg+ 34 000 283
SA977 mutS+ Rec+ Arg+ 35 1
SA977 mutSD680 Rec+ Arg+ 10 665 296
SA977 mutSD800 Rec+ Arg+ 3410 100
SA536 mutS+ recA56 Arg+ 30 1
SA536 mutSD680 recA56 Arg+ 80 2.7
SA536 mutSD800 recA56 Arg+ 60 2
SA977 mutS+ recA56 Arg+ 8 1
SA977 mutSD680 recA56 Arg+ 120 15
SA977 mutSD800 recA56 Arg+ 85 10
Donor and recipient (GM4799 and GM5550) cultures (at 1–2· 108 cells per ml)
were mated for 60 min (AB259) or 3 h (SA strains). The numbers in the table
represent the Thr+Leu+ [StrR] or Arg+ [StrR] recombinants in 50 ml of undiluted
mating mixture.
Figure 1. Gal reversion assay. Dark Gal+ revertants are shown on a background
of white Gal colonies. From left to right: the GM4799 strain (mutS null
mutation) with plasmids bearing mutS+, mutSD680 and mutSD800, respectively.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1195
 at M
edical Center Library on M
arch 29, 2010 
http://nar.oxfordjournals.org
D
ow
nloaded from
 
the same with either strain GM4799 or GM4799 containing the
mutSD680 plasmid (data not shown).
To ensure that the results of the crosses described above
were due to recombination, we repeated the crosses with
a recombination-deficient (recA56) derivative of GM4799,
GM5550. With the E.coli donor, AB259, no recombinants
were detected in any of the crosses with the GM5550 recipi-
ents (data not shown). With the Salmonella donors, there was
more than a 99% decrease in recombinant formation in the
GM5550 strains with the mutSD800 and mutSD680 plasmids.
We conclude that the mutSD800 mutation significantly reduces
antirecombination in interspecies crosses in a recA-dependent
manner.
Sensitivity to cytotoxic agents
E.coli dam mutants are more sensitive to cisplatin and MNNG
than wild type (11,12). Figure 2A shows that a dam mutS
strain, GM5556, carrying the mutS+ plasmid is more sensitive
to cisplatin than the same strain bearing the mutSD680 (null
mutation) plasmid or the mutSD800 plasmid, indicating that
the mutSD800 gene product is unable to promote MMR sens-
itization. Figure 2A also shows that the survival of GM3819,
a dam mutS+ strain, with the mutSD800 plasmid is the same as
with a mutS+ plasmid. This result indicates that the mutSD800
allele in multicopy does not have a dominant-negative pheno-
type in wild-type (mutS+) cells.
Figure 2B shows that when exposed to MNNG, the GM5556
strain with the mutS+ plasmid is sensitive but that with the
mutSD680 plasmid is resistant. In contrast to the results with
cisplatin, GM5556 with the mutSD800 plasmid has the same
survival as the strain with the mutS+ plasmid.
The simplest interpretation of the data in Figure 2 is that
while the MutSD800 protein is unable to recognize diguanyl
platinated cross-links, it can recognize O6-meG mismatches
with enough efficiency to produce the same phenotype in cells
as MutS.
MutS and MutSD800 binding to platinated
oligonucleotides
To investigate if MutS and MutSD800 have altered binding to
cisplatin cross-links, we tested the ability of both proteins to
bind to homoduplex, heteroduplex and platinated DNA
substrates in an electrophoretic mobility shift assay. The data
in Figure 3 show that MutSD800 has approximately the same
affinity for P32-labeled heteroduplex DNA with a single base
Figure 3. Binding isotherm of MutS and MutSD800 to heteroduplex DNA.
The upper panel shows the binding of MutS and MutSD800 to a P32-labeled
heteroduplex DNA with a single base IDL. The heteroduplex concentration
was 0.6 pmol. The data are shown in the lower panel as a binding isotherm.
Figure 2. Survival of cells exposed to cisplatin and MNNG. Cell survival of strain GM5556 (Ddam-16::Kan mutS::Tn10) containing plasmids with mutS+ (closed
circles), mutSD680 (inverted triangles), and mutSD800 (closed squares) after exposure to cisplatin (A) and MNNG (B). The open squares in (A) represent the survival
of GM3819 (Ddam-16::Kan mutS+) with the mutSD800 plasmid.
1196 Nucleic Acids Research, 2005, Vol. 33, No. 4
 at M
edical Center Library on M
arch 29, 2010 
http://nar.oxfordjournals.org
D
ow
nloaded from
 
IDL as MutS. There was no significant binding of these
proteins to a fully base-paired homoduplex substrate under
the same experimental conditions (data not shown).
The substrates for MutS binding to platinated DNA included
unplatinated homoduplex DNA, unplatinated heteroduplex
DNA with a G–T mismatch, and derivatives of each of these
with a single intrastrand diguanyl cross-link (Figure 4). The
unplatinated homoduplex acts as a negative control for the
diguanyl cross-link paired with CC, and is considered to be
a biologically relevant adduct produced from the reaction of
cisplatin and DNA. The GG–CT substrate acts as a positive
control ensuring that MutS can bind to mismatched DNA in
this sequence context. The mobility shifts shown in Figure 4
were monitored by fluorescence after staining with Vistra-
Green. As expected, there was no detectable band shifting
with MutS and MutSD800 to unplatinated homoduplex DNA
at the concentrations used for specific binding (Figure 4A,
lanes 2–5). In contrast to the results in Figure 3, where
MutS and MutSD800 bind the IDL with near equivalent affin-
ity, we did detect a difference in binding between MutS and
MutSD800 to the unplatinated heteroduplex containing a G–T
mismatch (Figure 4B, lanes 2–5). The addition of 4 mM of
MutS produced a discernible retardation of the oligonucleo-
tide (lane 3) while, at the same concentration, MutSD800 did
not (lane 5). At this concentration, MutS forms two distinct
bands (lane 3), only one of which is present with MutSD800
(lane 5) and may indicate that MutS first binds as a dimer and
subsequently is converted to a tetramer. With 8 mM, the extent
of heteroduplex binding by MutSD800 was about 80% that of
MutS (lanes 2 and 4).
There was a significant difference in binding of MutS
and MutSD800 to DNA with a GG cross-link opposite two
C residues (Figure 4A, lanes 6–10). In fact, no binding of
MutSD800 to this DNA was observed (Figure 4A, lanes 9
and 10) although MutS, at the same concentration, did produce
a considerable band shift (Figure 4A, lanes 7 and 8). On the
other hand, the DNA with a GG cross-link opposite CT
residues, a product of translesion polymerase synthesis,
was bound by MutSD800 to about the same extent as MutS
at 4 nM but less so at 8 nM due to partial shifting (Figure 4B,
lanes 6–10). With this substrate, the MutS and MutSD800
upper bands are at about the same location. This could be due
to MutSD800 recognizing this substrate as a G–T mismatch
and the presence of the platinated guanines or that MutSD800
arrays on this substrate to a greater extent than MutS.
The results in Figure 4C show that both MutS and
MutSD800 were able to bind to a duplex DNA with a single
O6-meG–C (lanes 1–4) or O6-meG–T (lanes 5–8). There was
no binding to homoduplex DNA at the concentrations used
(data not shown). The difference in the binding affinities of
MutSD800 for the types of heteroduplexes used in Figures 3
and 4 are relevant because the affinity of these proteins for the
same substrate can differ due to sequence context or the type
of mismatch or the affinity for base mismatches versus a one
base IDL.
MutSD800, therefore, has impaired specific binding of
platinated intrastrand GG–CC cross-links, but not intrastrand
GG–CT cross-links or a single base IDL or O6-meG–C or
O6-meG–T mismatches. Since MutS can form tetramers
while MutSD800 cannot, this suggests that the ability to form
tetramers could be necessary for efficient MutS processing of
the biologically relevant platinated intrastrand cross-link.
RecA-mediated strand exchange in vitro
In this assay, the ability of MutS to inhibit RecA-mediated
strand transfer between M13–M13 (homologous) and M13-fd
(homeologous) phage DNA molecules is measured (8).
Figure 5 shows the results of a typical assay. For the
M13–M13 homologous substrates (lanes a–e), nicked circle
(NC) product and intermediate (I) bands are visible after 5 min
(lane b) and these increase and decrease, respectively, during
the reaction (lanes c–e). The homeologous M13-fd reaction
(lanes f–j), is clearly slower, with no nicked circle product
visible at 5 min (lane g) and a lower yield (72%) at 90 min
(lane j). The graph in Figure 6 shows that the addition of
100 nM MutS or MutSD800 has no effect on the rate or
yield of the reaction using the homologous M13–M13 sub-
strates. Addition of 25 or 100 nM MutS, however, reduces
exchange between homeologous M13-fd substrates by 48%
Figure 4. Binding of MutS and MutSD800 to modified DNA. (A) The binding of MutS and MutSD800 to unplatinated (lanes 1–5) and platinated homoduplex
(lanes 6–10) DNA. No enzyme (lanes 1 and 6); MutS, 8 mM (lanes 2 and 7) and 4 mM (lanes 3 and 8); and MutSD800, 8 mM (lanes 4 and 9) and 4 mM (lanes 5 and 10).
The DNA was visualized by staining the gel with Vistra Green. (B) The binding of MutS and MutSD800 to unplatinated (lanes 1–5) and platinated heteroduplex
(lanes 6–10). Protein additions are the same as in (A). (C) The binding of MutS and MutSD800 to O6-meG–C (lanes 1–4) and O6-meG–T (lanes 5–8) DNA. MutS,
8 mM (lanes 1 and 5) and 16 mM (lanes 2 and 6); and MutSD800, 8 mM (lanes 3 and 7) and 16 mM (lanes 4 and 8).
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and 98%, respectively (Figure 6A). When MutSD800 is added,
the corresponding percentages were 22% and 58%, respect-
ively (Figure 6B).
Worth et al. (8) showed that MutL stimulates MutS binding
to M13-fd homeologous duplexes when the latter is at a sub-
optimal concentration. In the experiment shown in Figure 6,
25 nM MutS or MutSD800 only partially inhibits RecA-
catalyzed strand transfer. Inclusion of MutL, at 15 or 40 nM
to these reactions, however, completely abolishes RecA trans-
fer activity (Figure 6) indicating that MutL dimers can interact
with MutS or MutSD800. MutL by itself had no effect on the
rate or product yield in the reaction. We showed previously
that there was no binding of MutL alone to platinated cross-
linked DNA (17).
DISCUSSION
The results described in this report show that MutS and
MutSD800 proteins, produced from multicopy plasmids,
impart different properties to cells. Although cells with the
MutSD800 or MutS protein are not mutators (Table 1 and
Figure 1), the MutSD800-containing cells are deficient in
antirecombination (Table 2) and not sensitized to cisplatin
cytotoxicity (Figure 2A). This is the first demonstration of
a separation of function phenotype for an E.coli mutS muta-
tion. We propose that the C-terminal domain of MutS is
required for efficient antirecombination and cisplatin sensit-
ization, but not mutation avoidance or MNNG sensitization.
Given that MutSD800 can only form monomers and dimers,
we postulate that the inability to form tetrameric MutS could
be responsible for this phenotype. The data reported here also
suggests that although MutS and MutSD800 may bind base
mismatches as dimers, conversion to the terameric form may
be required for subsequent reactions in mismatch repair.
The results we have obtained in this report are best
explained by the findings of Bjornson et al. (23) who have
argued that the MutS tetramer is likely the active form of MutS
in mutation avoidance. To support this conclusion, they found
that MutSD800 protein bound to mismatched DNA less effi-
ciently than MutS. Our results also indicate that MutSD800
does have reduced affinity for GG–CT base mismatches
(Figure 4B) but not with the one base IDL (Figure 3) or
O6-meG mismatches (Figure 4C). Given that MutSD800 has
reduced affinity for some base mismatches, we propose that
the lack of a mutator phenotype in cells over-expressing
MutSD800 (Table 1 and Figure 1) can be explained by the
MutS dimer being able to cope with the few mismatches
generated behind the replication fork. The atomic structure
of MutSD800 indicates that mismatch binding does occur.
Figure 6. Kinetics of MutS inhibition of RecA-mediated strand exchange. The graphs show the effect of varying concentrations of MutS (A) and MutSD800
(B) on RecA strand exchange using homologous (M13–M13) and homeologous (M13-fd). Closed circles, M13–M13; crosses, M13–M13 plus 100 nM protein;
closed squares, M13-fd; open squares, M13-fd plus 25 nM protein; open circles, M13-fd plus 100 nM protein; and inverted triangles, M13-fd plus 25 nM protein plus
40 nM MutL.
Figure 5. RecA-catalyzed strand transfer. The upper panel shows a schematic
diagram of the reaction. Single-strand (SS) circular DNA reacts with linear (L)
duplex to form intermediate (I) structures which are converted into nicked-
circle (NC) products. The fluorograph shows the results from the homologous
M13–M13 (lanes a–e) and the homeologous M13-fd (lanes f–j) reactions.
Samples were removed at time 0 (lanes a and f), 5 min (lanes b and g),
15 min (lanes c and h), 45 min (lanes d and i) and 90 min (lanes e and j).
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In interspecies crosses, however, the much larger number of
mismatches overwhelms the MutSD800 protein’s reduced
mismatch binding and processing ability, thereby leading to
reduced antirecombination as shown in Table 2. An essential
part of our proposal, therefore, is that the cell’s response with
dimeric MutS depends on the number of mismatches involved;
if there are few, overproduced dimeric MutS can substitute for
tetrameric MutS at its normal cellular concentration. The data
in Figures 5 and 6, showing a greater amount of M13-fd
heteroduplex formation by MutSD800 compared to MutS,
is consistent with this model. The combination of MutL
and MutSD800 is as effective as MutS and MutL where the
level of mismatching is 3%. We predict that at higher levels of
mismatching, such as the 17% in E.coli–Salmonella crosses,
MutSD800 would be much less effective than MutS, even in
the presence of MutL.
Bjornson et al. (23) also showed that MutH-induced
incision of heteroduplex DNA, in the presence of MutL,
was reduced by MutSD800. This observation can also help to
explain the response of dam mutants with the over-expressed
MutSD800 protein to cisplatin and MNNG. For cells exposed
to MNNG, there is sufficient binding of MutSD800 to O6-meG
mismatches to provoke a sensitization response even though
there is reduced MutH-induced incision (Figure 2B). For dam
cells expressing MutSD800 and exposed to cisplatin, however,
the reduced binding of MutSD800 to intrastrand diguanyl-
cisplatin cross-links and the reduced MutH-induced incision
activity allow the cell to repair, by recombination, the few
DSBs that might be formed (Figure 2B).
The model proposed above regarding the number of
mismatched base pairs and the ability of over-expressed
MutSD800 to deal with them makes the strong prediction
that when MutSD800 is expressed from a single-copy gene,
the dam cells containing it would have different responses for
spontaneous mutagenesis and resistance to cisplatin and
MNNG compared to expression from a multicopy plasmid.
Experiments to test this prediction are in progress.
Surprisingly, MutSD800 when expressed in a wild-type
background does not display a dominant negative phenotype
with regard to cisplatin sensitivity (Figure 2). This result
appears to rule out the possibility that MutS, which is at a
low cellular concentration, could be titrated out by the plasmid
expressed MutSD800, leading to a dominant negative pheno-
type. We have not yet quantitated the protein levels of the
plasmid expressed MutSD800 versus the chromosomally
expressed copy of MutS. If the MutSD800 protein is less stable
than MutS, then the ratio of the two proteins may be such that
active mixed multimers are formed allowing for near-full
functionality of the protein (Figure 2), which is absent in a
population containing only the MutSD800.
The results in Figure 4 indicate that the C-terminal end of
MutS is required for binding to platinated GG–CC cross-links,
which could also indicate a requirement for MutS tertamer-
ization, in that the dimeric MutSD800 cannot recognize the
lesion, whereas the MutS does. At present, it is not known
how this cross-link opposite CC differs in structure from that
opposite CT to allow efficient recognition by MutS, but it is
possible that binding to a platinated lesion requires critical
contacts with residues residing in the C-terminus of MutS,
offering an alternative to the tetramerization requirement.
Furthermore, deletion of the C-terminus may disrupt the
binding of MutS to low-affinity lesions, such as the intrastrand
GG cross-links (10- to 40-fold lower than a G–T mismatch
(20,23), but not to a high affinity one base IDL (Figure 3).
Either explanation is supported by the survival results for cells
with the mutSD800 plasmid exposed to cisplatin (Figure 2). In
addition to these alternatives to tetramerization, we cannot rule
out a critical loss of interaction(s) between MutSD800 and
other proteins, such as the beta-clamp (32) which can ulti-
mately affect the efficiency of recognition or repair processes.
That MutS can bind to platinated GG–CC cross-links sug-
gests that MMR-induced DSBs can occur in unreplicated DNA
of dam mutants at these sequences, as well as cross-links
opposite CT bases, which can be formed by translesion poly-
merases (33,34). Platinated GG–CC cross-links can also be
formed during recombinational repair of DSBs and these are
bound by MutS which can block further branch migration (17),
thereby preventing DSB repair. The ability of MutS to bind
these cross-links can explain the observed cisplatin sensitivity
of the dam mutS+ strain in Figure 2A. In contrast, the decreased
binding of MutSD800 to such lesions reduces the number of
mismatch repair-induced DSBs and thereby promotes survival
of the dam mutSD800 strain to cisplatin (Figure 2A).
Finally, we note that mammalian cell lines also show
sensitivity to cisplatin and MNNG and MMR-deficient lines
derived from them are resistant to both compounds (35,36),
although whether cisplatin resistance is due specifically
to MMR-deficiency has recently been challenged (37,38).
Cisplatin-resistant cells isolated from patients treated with this
drug have also been shown to be deficient in MMR (39). Like
the bacterial MutS protein, the human MutS-alpha counterpart
also binds to cisplatin intrastrand cross-links and O6-meG
mismatches (40). The various models proposed to explain
mismatch repair-dependent drug-resistance in mammalian
cells have been reviewed in (41). The data reported here with
E.coli MutSD800 have no counterpart in eukaryotic systems,
thereby preventing selection of one model over another.
ACKNOWLEDGEMENTS
We thank Meindert Lamers and Titia Sixma for the mutSDC800
plasmid; Kenneth Sanderson for the Salmonella donor strains;
Jennifer Robbins for construction and purification of the cross-
linked platinated oligonucleotide; Dianne Schwarz for assis-
tance with the radiolabeled band shifts; F. Lopez de Saro and
M. O’Donnell for the gift of MutL protein and Mary Munson
for invaluable help and guidance during protein purification.
This work was supported by grant GM63790 from the National
Institutes of Health. Funding to pay the Open Access publica-
tion charges for this article was provided by the National
Institutes of Health.
REFERENCES
1. Modrich,P. and Lahue,R. (1996) Mismatch repair in replication fidelity,
genetic recombination, and cancer biology. Annu. Rev. Biochem., 65,
101–133.
2. Schofield,M.J. and Hsieh,P. (2003) DNA mismatch repair: molecular
mechanisms and biological function. Annu. Rev. Microbiol., 57,
579–608.
3. Marti,T.M., Kunz,C. and Fleck,O. (2002) DNA mismatch repair and
mutation avoidance pathways. J. Cell Physiol., 191, 28–41.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1199
 at M
edical Center Library on M
arch 29, 2010 
http://nar.oxfordjournals.org
D
ow
nloaded from
 
4. Rayssiguier,C., Thaler,D.S. and Radman,M. (1989) The barrier to
recombination between Escherichia coli and Salmonella typhimurium is
disrupted in mismatch-repair mutants. Nature, 342, 396–401.
5. Westmoreland,J., Porter,G., Radman,M. and Resnick,M.A. (1997)
Highly mismatched molecules resembling recombination intermediates
efficiently transform mismatch repair proficient Escherichia coli.
Genetics, 145, 29–38.
6. Harfe,B.D. and Jinks-Robertson,S. (2000) DNA mismatch repair and
genetic instability. Annu. Rev. Genet., 34, 359–399.
7. Fabisiewicz,A. and Worth,L.,Jr (2001) Escherichia coli MutS,L
modulate RuvAB-dependent branch migration between diverged DNA.
J. Biol. Chem., 276, 9413–9420.
8. Worth,L., Clark,S.R.M. and Modrich,P. (1994) Mismatch repair proteins
MutS and MutL inhibit RecA-catalyzed strand transfer between
diverged DNAs. Proc. Natl Acad. Sci. USA, 91, 3238–3241.
9. Junop,M.S., Yang,W., Funchain,P., Clendenin,W. and Miller,J.H. (2003)
In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation
of mismatch repair and DNA recombination. DNA Repair (Amst.),
2, 387–405.
10. Wu,T.H. and Marinus,M.G. (1994) Dominant negative mutator
mutations in the mutS gene of Escherichia coli. J. Bacteriol.,
176, 5393–5400.
11. Karran,P. and Marinus,M.G. (1982) Mismatch correction at
O6-methylguanine residues in E.coli DNA. Nature, 296, 868–869.
12. Fram,R.J., Cusick,P.S., Wilson,J.M. and Marinus,M.G. (1985) Mismatch
repair of cis-diamminedichloroplatinum(II)-induced DNA damage.
Mol. Pharmacol., 28, 51–55.
13. Marinus,M.G. (2005) Dr Jekyll and Mr Hyde: how the MutSLH repair
system kills the cell. In Higgins,N.P. (ed.), The Bacterial
Chromosome. ASM Press, Washington, DC, pp. 413–430.
14. Au,K.G., Welsh,K. and Modrich,P. (1992) Initiation of methyl-directed
mismatch repair. J. Biol. Chem., 267, 12142–12148.
15. Marinus,M.G. (2000) Recombination is essential for viability of an
Escherichia coli dam (DNA adenine methyltransferase) mutant.
J. Bacteriol., 182, 463–468.
16. Nowosielska,A. and Marinus,M.G. (2005) Cisplatin induces DNA
double-strand break formation in Escherichia coli dam mutants. DNA
Repair (Amst.), in press.
17. Calmann,M.A. and Marinus,M.G. (2004) MutS inhibits RecA-mediated
strand exchange with platinated DNA substrates. Proc. Natl Acad. Sci.
USA, 101, 14174–14179.
18. Su,S.S. and Modrich,P. (1986) Escherichia coli mutS-encoded protein
binds to mismatched DNA base pairs. Proc. Natl Acad. Sci. USA,
83, 5057–5061.
19. Parker,B.O. and Marinus,M.G. (1992) Repair of DNA heteroduplexes
containing small heterologous sequences in Escherichia coli.
Proc. Natl Acad. Sci. USA, 89, 1730–1734.
20. Fourrier,L., Brooks,P. and Malinge,J.M. (2003) Binding discrimination
of MutS to a set of lesions and compound lesions (base damage and
mismatch) reveals its potential role as a cisplatin-damaged DNA
sensing protein. J. Biol. Chem., 278, 21267–21275.
21. Rasmussen,L.J. and Samson,L. (1996) The Escherichia coli MutS DNA
mismatch binding protein specifically binds O(6)-methylguanine
DNA lesions. Carcinogenesis, 17, 2085–2088.
22. Lamers,M.H., Perrakis,A., Enzlin,J.H., Winterwerp,H.H., de Wind,N.
and Sixma,T.K. (2000) The crystal structure of DNA mismatch repair
protein MutS binding to a G · T mismatch. Nature, 407, 711–717.
23. Bjornson,K.P., Blackwell,L.J., Sage,H., Baitinger,C., Allen,D. and
Modrich,P. (2003) Assembly and molecular activities of the
MutS tetramer. J. Biol. Chem., 278, 34667–34673.
24. Takamatsu,S., Kato,R. and Kuramitsu,S. (1996) Mismatch DNA
recognition protein from an extremely thermophilic bacterium,
Thermus thermophilus HB8. Nucleic Acids Res., 24, 640–647.
25. Biswas,I., Ban,C., Fleming,K.G., Qin,J., Lary,J.W., Yphantis,D.A.,
Yang,W. and Hsieh,P. (1999) Oligomerization of a MutS mismatch repair
protein from Thermus aquaticus. J. Biol. Chem., 274, 23673–23678.
26. Obmolova,G., Ban,C., Hsieh,P. and Yang,W. (2000) Crystal structures of
mismatch repair protein MutS and its complex with a substrate DNA.
Nature, 407, 703–710.
27. Wu,T.H. and Marinus,M.G. (1999) Deletion mutation analysis of the
mutS gene in Escherichia coli. J. Biol. Chem., 274, 5948–5952.
28. Marinus,M.G. and Morris,N.R. (1974) Biological function for
6-methyladenine residues in the DNA of Escherichia coli K12.
J. Mol. Biol., 85, 309–322.
29. Nowosielska,A., Calmann,M.A., Zdraveski,Z., Essigmann,J.M. and
Marinus,M.G. (2004) Spontaneous and cisplatin-induced recombination
in Escherichia coli. DNA Repair (Amst.), 3, 719–728.
30. Rosen,H. (1957) A modified ninhydrin colorimetric analysis for amino
acids. Arch. Biochim. Biophys., 67, 10–15.
31. Biswas,I., Obmolova,G., Takahashi,M., Herr,A., Newman,M.A.,
Yang,W. and Hsieh,P. (2001) Disruption of the helix–u-turn–helix motif
of MutS protein: loss of subunit dimerization, mismatch binding and
ATP hydrolysis. J. Mol. Biol., 305, 805–816.
32. Lopez de Saro,F.J. and O’Donnell,M. (2001) Interaction of the beta
sliding clamp with MutS, ligase, and DNA polymerase I. Proc. Natl Acad.
Sci. USA, 98, 8376–8380.
33. Vaisman,A. and Chaney,S.G. (2000) The efficiency and fidelity of
translesionsynthesis past cisplatinandoxaliplatinGpG adducts byhuman
DNA polymerase beta. J. Biol. Chem., 275, 13017–13025.
34. Vaisman,A., Masutani,C., Hanaoka,F. and Chaney,S.G. (2000) Efficient
translesion replication past oxaliplatin and cisplatin GpG adducts by
human DNA polymerase eta. Biochemistry, 39, 4575–4580.
35. Branch,P., Masson,M., Aquilina,G., Bignami,M. and Karran,P. (2000)
Spontaneous development of drug resistance: mismatch repair and p53
defects in resistance to cisplatin in human tumor cells. Oncogene,
19, 3138–3145.
36. Kartalou,M. and Essigmann,J.M. (2001) Mechanisms of resistance to
cisplatin. Mutat. Res., 478, 23–43.
37. Massey,A., Offman,J., Macpherson,P. and Karran,P. (2003) DNA
mismatch repair and acquired cisplatin resistance in E. coli and human
ovarian carcinoma cells. DNA Repair (Amst.), 2, 73–89.
38. Claij,N. and Te Riele,H. (2004) Msh2 deficiency does not contribute
to cisplatin resistance in mouse embryonic stem cells. Oncogene,
23, 260–266.
39. Fink,D., Nebel,S., Aebi,S., Zheng,H., Cenni,B., Nehme,A.,
Christen,R.D. and Howell,S.B. (1996) The role of DNA mismatch repair
in platinum drug resistance. Cancer Res., 56, 4881–4886.
40. Duckett,D.R., Drummond,J.T., Murchie,A.I., Reardon,J.T., Sancar,A.,
Lilley,D.M. and Modrich,P. (1996) Human MutSalpha recognizes
damaged DNA base pairs containing O6-methylguanine,
O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl
Acad. Sci. USA, 93, 6443–6447.
41. Stojic,L., Brun,R. and Jiricny,J. (2004) Mismatch repair and DNA
damage signalling. DNA Repair (Amst.), 3, 1091–1101.
1200 Nucleic Acids Research, 2005, Vol. 33, No. 4
 at M
edical Center Library on M
arch 29, 2010 
http://nar.oxfordjournals.org
D
ow
nloaded from
 
